Advancing Tomorrow’s Cancer Medicines: Jacob Van Naarden Talks with Ken Herrmann and Johannes Czernin About Corporate Approaches to New Therapeutics Development

By sjmartinez • January 24, 2025

Van Naarden JS, Herrmann K, Czernin J. Advancing Tomorrow's Cancer Medicines: Jacob Van Naarden Talks with Ken Herrmann and Johannes Czernin About Corporate Approaches to New Therapeutics Development. J Nucl Med. 2025 Jan 23:jnumed.124.269354. doi: 10.2967/jnumed.124.269354. Epub ahead of print. PMID: 39848767.

Tags: Cardiology/Epi, Publications

Interventional procedures in congenital heart disease for atrio-ventricular valves: future possibility or fools dream

Linnane N, Kenny D. Interventional procedures in congenital heart disease for atrio-ventricular valves: future possibility or fools dream. Curr Opin Cardiol. 2026 May 5. doi:[...]

Cardiovascular-specific PTH1R activation enhances exercise-induced cardiac remodeling in a mouse model of calcific atherosclerosis

Hon A, Lu M, Shao XM, Demer LL, Tintut Y. Cardiovascular-specific PTH1R activation enhances exercise-induced cardiac remodeling in a mouse model of calcific atherosclerosis. Biochem[...]

In-Hospital Initiation of SGLT2 Inhibitors in Patients with Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials with Trial Sequential Analysis

Ahmed M, Rana JS, Sajjad L, Zulfiqar E, Chandak V, Tul Ain Q, Ahmed R, Mentz RJ, Fonarow GC. In-Hospital Initiation of SGLT2 Inhibitors in[...]